Combined use of pharmacokinetic modeling and a steady-state delivery approach allows early assessment of IκB kinase-2 (IKK-2) target safety and efficacy

Journal of Pharmaceutical Sciences

Volumn 99, Issue 3, 2010, Pages 1278-1287

  Chiang, Po Chang ^a   Kishore, Nandini N ^a   Thompson, David C ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Dose response; Efficacy; IKK; In vivo; I B; NF B; NOAEL; Oral; Pharmacokinetic; Safety; Steady state

Indexed keywords

I KAPPA B KINASE; I KAPPA B KINASE 2; I KAPPA B KINASE INHIBITOR; PHA 408; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC ARTHRITIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG TARGETING; FEMALE; HEPATITIS; IN VIVO STUDY; LYMPHOCYTE DEPLETION; MALE; NEUTROPHILIA; NONHUMAN; PHYSICAL CHEMISTRY; RAT; STEADY STATE;

EID: 76649131543     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21909     Document Type: Article

References (32)

1. Baeuerle PA, Henkel T. 1994. Function and activation of NF-kappaB in the immune system. Annu Rev Immunol 12:141-179.
2. Karin M, Greten FR. 2005. NF-[kappa]B: Linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5:749-759.
3. Chen Z, Hagler J, Palombella VJ, Melandri F, Scherer D, Ballard D, Maniatis T. 1995. Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitin-proteasome pathway. Genes Dev 9:1586-1597.
4. DiDonato JA, Mercurio F, Karin M. 1995. Phosphorylation of I kappa B alpha precedes but is not sufficient for its dissociation from NF-kappa B. Mol Cell Biol 15:1302-1311.
5. DiDonato J, Mercurio F, Rosette C, Wu-Li J, Suyang H, Ghosh S, Karin M. 1996. Mapping of the inducible IkappaB phosphorylation sites that signal its ubiquitination and degradation. Mol Cell Biol 16:1295-1304.
6. Bonizzi G, Karin M. 2004. The two NF-[kappa]B activation pathways and their role in innate and adaptive immunity. Trends Immunol 25:280-288.
7. Kishore N, Sommers C, Mathialagan S, Guzova J, Yao M, Hauser S, Huynh K, Bonar S, Mielke C, Albee L, Weier R, Graneto M, Hanau C, Perry T, Tripp CS. 2003. A selective IKK-2 inhibitor blocks NF-{kappa}B-dependent gene expression in interleukin-1{beta}-stimulated synovial fibroblasts. J Biol Chem 278:32861-32871.
8. Sakurai H, Chiba H, Miyoshi H, Sugita T, Toriumi W. 1999. Ikappa B kinases phosphorylate NF-kappa B p65 subunit on serine 536 in the transactivation domain. J Biol Chem 274:30353-30356.
9. Yang F, Tang E, Guan K, Wang C-Y. 2003. IKK{-beta} plays an essential role in the phosphorylation of RelA/p65 on serine 536 induced by lipopolysaccharide. J Immunol 170:5630-5635.
10. Mattioli I, Sebald A, Bucher C, Charles R-P, Nakano H, Doi T, Kracht M, Schmitz ML. 2004. Transient and selective NF-{kappa}B p65 serine 536 phosphorylation induced by T cell costimulation is mediated by I{kappa}B kinase {beta} and controls the kinetics of p65 nuclear import. J Immunol 172:6336-6344.
11. Karin M, Lin A. 2002. NF-[kappa]B at the crossroads of life and death. Nat Immunol 3:221-227.
12. Beg AA, Sha WC, Bronson RT, Ghosh S, Baltimore D. 1995. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-[kappa]B. Nature 376:167-170.
13. Li Q, Antwerp DV, Mercurio F, Lee K-F, Verma IM. 1999. Severe liver degeneration in mice lacking the IB kinase 2 gene. Science 284:321-325.
14. Rudolph D, Yeh W-C, Wakeham A, Rudolph B, Nallainathan D, Potter J, Elia AJ, Mak TW. 2000. Severe liver degeneration and lack of NF-kappa B activation in NEMO/IKKgamma -deficient mice. Genes Dev 14:854-862.
15. Tas SW, Adriaansen J, Hajji N, Bakker AC, Firestein GS, Vervoordeldonk MJ, Tak PP. 2006. Amelioration of arthritis by intraarticular dominant negative IKKbeta gene therapy using adeno-associated virus type 5. Human Gene Ther 17:821.
16. Li Z-W, Chu W, Hu Y, Delhase M, Deerinck T, Ellisman M, Johnson R, Karin M. 1999. The IKK-beta subunit of Ikappa B kinase (IKK) is essential for nuclear factor kappa B activation and prevention of apoptosis. J Exp Med 189:1839-1845.
17. Hu Y, Baud V, Delhase M, Zhang P, Deerinck T, Ellisman M, Johnson R, Karin M. 1999. Abnormal morphogenesis but intact IKK activation in mice lacking the IKK subunit of IB kinase. Science 284:316-320.
18. Burke JR, Pattoli MA, Gregor KR, Brassil PJ, MacMaster JF, McIntyre KW, Yang X, Iotzova VS, Clarke W, Strnad J, Qiu Y, Zusi FC. 2003. BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice. J Biol Chem 278:1450-1456.
19. McIntyre KW, Shuster DJ, Gillooly KM, Dambach DM, Pattoli MA, Lu P, Zhou XD, Qiu Y, Zusi FC, Burke JR. 2003. A highly selective inhibitor of I kappa B kinase, BMS-345541, blocks both joint inflammation and destruction in collagen-induced arthritis in mice. Arthritis Rheum 48:2652-2659.
20. Schopf L, Savinainen A, Anderson K, Kujawa J, DuPont M, Silva M, Siebert E, Chandra S, Morgan J, Gangurde P, Wen D, Lane J, Xu Y, Hepperle M, Harriman G, Ocain T, Jaffee B. 2006. IKKbeta inhibition protects against bone and cartilage destruction in a rat model of rheumatoid arthritis. Arthritis Rheum 54:3163-3173.
21. Yamamoto Y, Gaynor RB. 2001. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest 107:135-142.
22. Podolin PL, Callahan JF, Bolognese BJ, Li YH, Carlson K, Davis TG, Mellor GW, Evans C, Roshak AK. 2005. Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of I{kappa}B kinase 2, TPCA-1 (2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced T cell proliferation. J Pharmacol Exp Ther 312:373-381.
23. Ziegelbauer K, Gantner F, Lukacs NW, Berlin A, Fuchikami K, Niki T, Sakai K, Inbe H, Takeshita K, Ishimori M, Komura H, Murata T, Lowinger T, Bacon KB. 2005. A selective novel low-molecular-weight inhibitor of I[kappa]B kinase-[beta] (IKK-[beta]) prevents pulmonary inflammation and shows broad anti-inflammatory activity. Br J Pharmacol 145:178-192.
24. Wen D, Nong Y, Morgan JG, Gangurde P, Bielecki A, Dasilva J, Keaveney M, Cheng H, Fraser C, Schopf L, Hepperle M, Harriman G, Jaffee BD, Ocain TD, Xu Y. 2006. A selective small molecule IkappaB kinase beta inhibitor blocks nuclear factor kappaB-mediated inflammatory responses in human fibroblast-like synoviocytes, chondrocytes, and mast cells. J Pharmacol Exp Ther 317:989-1001.
25. Lavon I, Goldberg I, Amit S, Landsman L, Jung S, Tsuberi BZ, Barshack I, Kopolovic J, Galun E, Bujard H, Ben-Neriah Y. 2000. High susceptibility to bacterial infection, but no liver dysfunction, in mice compromised for hepatocyte NF-kappaB activation. Nat Med 6:573-577.
26. Nenci A, Becker C, Wullaert A, Gareus R, van Loo G, Danese S, Huth M, Nikolaev A, Neufert C, Madison B, Gumucio D, Neurath MF, Pasparakis M. 2007. Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature 446:557-561.
27. Beg AA, Sha WC, Bronson RT, Ghosh S, Baltimore D. 1995. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. Nature 376:167-170.
28. Nagashima K, Sasseville VG, Wen D, Bielecki A, Yang H, Simpson C, Grant E, Hepperle M, Harriman G, Jaffee B, Ocain T, Xu Y, Fraser CC. 2006. Rapid TNFR1-dependent lymphocyte depletion in vivo with a selective chemical inhibitor of IKKbeta. Blood 107:4266-4273.
29. Dressman JB, Amidon GL, Reppas C, Shah VP. 1998. Dissolution testing as a prognostic tool for oral drug absorption: Immediate release dosage forms. Pharm Res 15:11-22.
30. Mbalaviele G, Sommers CD, Bonar SL, Mathialagan S, Schindler JF, Guzova JA, Shaffer AF, Melton MA, Christine LJ, Tripp CS, Chiang PC, Thompson DC, Hu Y, Kishore N. 2009. A novel, highly selective, tight binding I{kappa}B kinase-2 (IKK-2) inhibitor: A tool to correlate IKK-2 activity to the fate and functions of the components of the NF-{kappa}B pathway in arthritis relevant cells and animal models. J Pharmacol Exp Ther 329:14-25.
31. Kuiper S, Joosten LAB, Bendele AM, Edwards Iii CK, Arntz OJ, Helsen MMA, Van de Loo FAJ, Van den Berg WB. 1998. Different roles of tumour necrosis factor [alpha] and interleukin 1 in murine streptococcal cell wall arthritis. Cytokine 10:690-702.
32. Kwon Y. 2001. Handbook of essential pharmacokinetics, pharmacodynamics, and drug metabolism for industrial scientists. 4th edition. New York, NY, USA: Kluwer Academic/Plenum Publishers.